The current PE ratio of AGIO cannot be calculated, as the latest EPS of -$7.25 is negative. Agios Pharmaceuticals's last PE ratio on record was 2.9 in June 2025.
The mean historical PE ratio of Agios Pharmaceuticals over the last six years is 2.49. Looking back at the last six years, AGIO's PE ratio peaked in the Sep 2024 quarter at 3.77, with a price of $44.43 and an EPS of $11.79. The Dec 2021 quarter marked the lowest point at 1.24, with a price of $32.87 and an EPS of $26.55.
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $27.22 | -$7.12 |
| 2024 | 2.77 | N/A | $32.86 | $11.86 |
| 2023 | N/A | N/A | $22.27 | -$6.33 |
| 2022 | N/A | N/A | $28.08 | -$4.23 |
| 2021 | 1.24 | N/A | $32.87 | $26.55 |
| 2020 | N/A | N/A | $43.33 | -$4.74 |
| 2019 | N/A | N/A | $47.75 | -$6.86 |
| 2018 | N/A | N/A | $46.11 | -$6.03 |
| 2017 | N/A | N/A | $57.17 | -$6.75 |
| 2016 | N/A | N/A | $41.73 | -$5.07 |
| 2015 | N/A | N/A | $64.92 | -$3.15 |
| 2014 | N/A | N/A | $112.04 | -$1.59 |
| 2013 | N/A | N/A | $23.95 | -$2.83 |
| 2012 | N/A | N/A | N/A | -$8.02 |
| 2011 | N/A | N/A | N/A | -$8.9 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | N/A | N/A | $33.83 | -$7.25 |
| Dec 2025 | N/A | N/A | $27.22 | -$7.12 |
| Sep 2025 | N/A | N/A | $40.14 | -$6.98 |
| Jun 2025 | 2.9 | 15.54% | $33.26 | $11.45 |
| Mar 2025 | 2.51 | -9.39% | $29.3 | $11.69 |
| Dec 2024 | 2.77 | -26.53% | $32.86 | $11.86 |
| Sep 2024 | 3.77 | N/A | $44.43 | $11.79 |
| Jun 2024 | N/A | N/A | $43.12 | -$6.5 |
| Mar 2024 | N/A | N/A | $29.24 | -$6.32 |
| Dec 2023 | N/A | N/A | $22.27 | -$6.33 |
| Sep 2023 | N/A | N/A | $24.75 | -$3.95 |
| Jun 2023 | N/A | N/A | $28.32 | -$3.8 |
| Mar 2023 | N/A | N/A | $22.97 | -$3.97 |
| Dec 2022 | N/A | N/A | $28.08 | -$4.23 |
| Sep 2022 | N/A | N/A | $28.28 | -$5.55 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
| Stock name | PE ratio | Market cap |
|---|---|---|
| EXEL Exelixis Inc | 16.88 | $13.23B |
| PFE Pfizer Inc | 19.63 | $146.56B |
| LLY ELI LILLY & Co | 39.92 | $1.06T |
| BMRN Biomarin Pharmaceutical Inc | 40.61 | $10.99B |
| XNCR Xencor Inc | N/A | $887.47M |
| AGIO Agios Pharmaceuticals Inc | N/A | $1.74B |
The current price to earnings ratio of AGIO cannot be determined, as its EPS of -$7.25 is negative.
The 5-year average price to earnings ratio for AGIO stock is 2.52.
Over the last six years, the Sep 2024 quarter recorded the highest quarterly PE ratio at 3.77.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.